Lurbinectedin is a medication used to treat certain types of cancer. According to the FDA-approved prescribing information [3], the recommended dosage of lurbinectedin is 3.2 mg/m² administered as an intravenous infusion over 60 minutes every 21 days until disease progression or unacceptable toxicity. The dosage should be adjusted for patients with hepatic or renal impairment.

Medscape [2] also confirms the recommended dosage of lurbinectedin as 3.2 mg/m² every 21 days. However, the article notes that the dosage may be delayed or reduced based on the patient's individual response and any adverse effects experienced.

Drug Patent Watch [1] provides additional information on the recommended dosage of lurbinectedin, stating that it is typically administered by a healthcare professional in a clinical setting. The dosage may be adjusted based on the patient's age, weight, and other medical conditions.

In summary, the recommended dosage of lurbinectedin is 3.2 mg/m² administered intravenously every 21 days until disease progression or unacceptable toxicity. The dosage may be adjusted based on individual patient factors. It is important to consult with a healthcare professional for specific dosing instructions.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://reference.medscape.com/drug/zepzelca-lurbinectedin-4000075
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf